[1] 徐兵河,王树森,江泽飞,等. 中国晚期乳腺癌维持治疗专家共识[J]. 中华普通外科学文献:电子版, 2018,12(1):1-5. [2] 高德宗. 激素受体阳性晚期转移性乳腺癌的内分泌治疗[J]. 中华乳腺病杂志:电子版, 2018, 12(2):69-72. [3] LIN M I, SESSA W C. Antiangiogenic therapy:creating a unique "window"of opportunity[J]. Cancer Cell, 2004,6(6):529-531. [4] 朱安婕,袁芃. 抗血管生成酪氨酸激酶抑制剂在晚期乳腺癌中的应用[J]. 中华乳腺病杂志:电子版,2018, 12(4):234-237. [5] 王雅婕,胡毅. 甲磺酸阿帕替尼治疗晚期恶性肿瘤的研究进展[J]. 解放军医学院学报,2018, 39(6):542-545,553. [6] XUE J, ASTERE M, ZHONG M, et al. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer:a meta-analysis[J].Oncotargets Ther, 2018, 11:6119-6128. [7] 桑蝶,张频,李青,等. 白蛋白结合型紫杉醇治疗多线化疗失败乳腺癌的疗效及安全性分析[J]. 临床药物治疗杂志,2018, 16(7):28-33. [8] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247. [9] HUGHES R. NCI-CTC vs TNS:which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?[J]. Nat Clin Pract Neurol,2008, 4(2):68-69. [10] ZHOU Z, YAO H, HU H. Disrupting tumor angiogenesis and "the hunger games" for breast cancer[J]. Adv Exp Med Biol, 2017, 1026:171-195. [11] HU X C, CAO J, HU W W, et al. Multicenter phase Ⅱ study of Apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer,2014, 14:820. [12] HU X, ZHANG J, XU B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer[J]. Int J Cancer, 2014, 135(8):1961-1969. [13] SEIDMAN A D. Gemcitabine as single-agent therapy in the management of advanced breast cancer[J]. Oncology(Williston Park),2001, 153(2 Suppl 3):11-14. [14] FUMOLEAU P, BLUM J L, REICHARDT P. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclinels and taxanes in metastatic breast carcinoma[J]. Cancer. 2003, 98(6):1325-1326. [15] SONG Y Q, LIU B L, GUAN M, et al. Successful treatment using apatinib in intractable brain edema:A case report and literatures review[J]. Cancer Biol Ther,2018,19(12):1093-1096. [16] 马莉,刘妍妍,糜志远. 阿帕替尼治疗乳腺癌的研究进展[J]. 大医生,2018(4):160-162. [17] ZHANG H J. Apatinib for molecular targeted therapy in tumor[J]. Drug Des Devel Ther,2015, 9:6075-6081. [18] 陈玲娟,伍钢,董晓荣,等. 阿帕替尼二线及二线以上治疗晚期肺癌26例[J]. 医药导报,2018, 37(5):551-554. [19] 时佳琪,刘超,张艳桥,等. 甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析[J]. 中国肿瘤临床,2018(4):191-195. [20] QIN S K. Apatinib in Chinese patients with advanced hepatocellular carcinoma:A phase Ⅱ randomized, open-label trial[J]. J Clin Oncol, 2014, 32(15_Suppl):4019. [21] LI J, QIN S K, XU J M, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:Results from a randomized, placebo-controlled, parallel-arm, phase Ⅱ trial[J]. J Clin Oncol, 2013, 31(26):3219-3225. |